Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285572 | 0.78 | F2 (0.50) | L3MBTL1CCR2F2PRSS1 | |
| SCHEMBL7552139 | 0.78 | CCR2 (0.49) | L3MBTL1CCR2APEX1MEN1KMT2A | |
| SCHEMBL4420702 | 0.77 | F2 (0.62) | F2PRSS1 | |
| SCHEMBL23460843 | 0.75 | HSD17B10 (0.43) | MAPTAPEX1F2PRSS1 | |
| SCHEMBL6282416 | 0.75 | L3MBTL1 (0.52) | L3MBTL1CCR2TP53MAPTAPEX1 | |
| SCHEMBL23461187 | 0.73 | KDM4E (0.47) | F2PRSS1 | |
| SCHEMBL6279039 | 0.73 | L3MBTL1 (0.59) | L3MBTL1CCR2APEX1MEN1KMT2A | |
| SCHEMBL4308750 | 0.72 | L3MBTL1 (0.66) | L3MBTL1APEX1MEN1KMT2A | |
| SCHEMBL22612111 | 0.70 | ALDH1A1 (0.55) | L3MBTL1MAPTRXFP1MEN1KMT2A | |
| SCHEMBL5141457 | 0.70 | MAPK1 (0.44) | L3MBTL1CCR2TP53MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-07-28 | — | — | US | disclosed |
| US-6870056-B1 | Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-22 | — | — | US | disclosed |
| US-6867217-B1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1178964-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069826-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165062-A1 | Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, TFPI2 | L3MBTL1 3640/4885CCR2 2505/4885TP53 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.